BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12324629)

  • 1. Management of treatment-related toxicity in advanced ovarian cancer.
    Dunton CJ
    Oncologist; 2002; 7 Suppl 5():11-9. PubMed ID: 12324629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the role of topotecan in the treatment of recurrent ovarian cancer.
    Herzog TJ
    Oncologist; 2002; 7 Suppl 5():3-10. PubMed ID: 12324628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with topotecan in relapsed ovarian cancer.
    Herzog TJ
    Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S3-7. PubMed ID: 13129489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
    Bookman MA
    Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal sequencing in the treatment of recurrent ovarian cancer.
    Spriggs D
    Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S39-44. PubMed ID: 13129495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer.
    Morris R; Munkarah A
    Oncologist; 2002; 7 Suppl 5():29-35. PubMed ID: 12324631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
    Lin H; Changchien CC
    Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized single-agents trials in recurrent epithelial ovarian cancer.
    Sessa C; Marsoni S
    Int J Gynecol Cancer; 2005; 15 Suppl 3():247-51. PubMed ID: 16343240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role of topotecan in front-line treatment of carcinoma of the ovary.
    Coleman RL
    Oncologist; 2002; 7 Suppl 5():46-55. PubMed ID: 12324633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapsed ovarian cancer: challenges and management strategies for a chronic disease.
    Armstrong DK
    Oncologist; 2002; 7 Suppl 5():20-8. PubMed ID: 12324630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
    Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
    Gordon AN; Tonda M; Sun S; Rackoff W;
    Gynecol Oncol; 2004 Oct; 95(1):1-8. PubMed ID: 15385103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pros and cons for systemic therapy in recurrent ovarian cancer.
    Oskay-Ozcelik G; Sehouli J
    Anticancer Res; 2009 Jul; 29(7):2831-6. PubMed ID: 19596970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current concepts of treatment strategies in advanced or recurrent ovarian cancer.
    Salzberg M; Thurlimann B; Bonnefois H; Fink D; Rochlitz C; von Moos R; Senn H
    Oncology; 2005; 68(4-6):293-8. PubMed ID: 16020955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.